As CD68<sup>+</sup> tumour-associated macrophages (TAMs) drive TME suppression and poor prognosis in non-translocation-driven STS, we evaluated Regnase-1 and CD68<sup>+</sup> TAMs to assess Regnase-1 as an indicator of an immunologically activated TME.<h4>Methods</h4>Immunohistochemistry scoring of Regnase-1 and CD68<sup>+</sup> TAMs was performed in 91 patients. This evidence concerns the gene CD68 and neoplasm.